Key result
Germline PRKAR1A variants occur in ~71% of PPNAD cases, most presenting with overt Cushing syndrome.
Why the study?
PPNAD is a rare cause of ACTH-independent Cushing syndrome, and its phenotypic and molecular spectra remain incompletely defined.
Observational (n=38)
PPNAD and Carney complex exhibit marked phenotypic variability and diverse molecular mechanisms, highlighting the importance of systematic genetic screening.
May support PRKAR1A screening in suspected Carney complex; leaves open optimal surveillance amid phenotypic variability.
CONTEXT: Primary pigmented nodular adrenocortical disease (PPNAD) is a rare cause of ACTH-independent Cushing syndrome (CS), occurring in isolation or as part of Carney complex (CNC); its phenotypic and molecular spectra remain incompletely defined. OBJECTIVE: To characterize phenotypic variability, genotype-phenotype correlations, and molecular findings in PPNAD through integrated clinical, histopathological, and genetic analyses. METHODS: We evaluated 18 index patients with PPNAD (15 with CNC, 3 isolated) and performed cascade genetic screening in relatives (20 variants-positive). Clinical, hormonal, imaging and histopathological data were reviewed; germline and somatic analyses employed targeted next-generation sequencing and copy-number assessment. RESULTS: Overt CS was present in 83% of index cases; 17% had cyclic hypercortisolism. Pathogenic or likely-pathogenic germline PRKAR1A variants were identified in 70.6% probands, including four novel variants; germline PRKACA duplications were detected in two cases. Cascade screening identified eight asymptomatic variant-positive relatives, in whom mild autonomous cortisol secretion (MACS) was observed. Somatic second-hit alterations in tumor tissue included PRKACA duplication, a PRKAR1A frameshift deletion, and 17q24.2 loss of heterozygosity. Histology most often showed classic PPNAD but also nonclassical patterns, expanding the morphological spectrum. Extra-adrenal manifestations were frequent (lentigines 61%, cardiac myxomas 22%). CONCLUSION: In this referral cohort, PPNAD/CNC displays marked phenotypic variability, incomplete penetrance with subclinical cortisol excess, and diverse molecular mechanisms, including novel germline variants and somatic second hits. Some cases lacked identifiable drivers, suggesting additional uncharacterized mechanisms. Systematic genetic screening and recognition of MACS are important for early diagnosis and long-term management.
No takes yet. Share an insight, caveat, or question.
Kuhn et al. (2026) conducted an observational in Primary pigmented nodular adrenocortical disease (PPNAD) (n=38). Primary pigmented nodular adrenocortical disease (PPNAD) was evaluated on Phenotypic variability and molecular findings (including overt Cushing syndrome and pathogenic germline PRKAR1A variants). In 18 index patients with PPNAD, overt Cushing syndrome was present in 83% of cases, and pathogenic germline PRKAR1A variants were identified in 70.6% of probands.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: